

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-11 (Canceled)

12. (Original) Monoclonal antibody as deposited under DSM ACC 2457.

13. (Currently Amended) A method for identifying a cancer cell comprising:

(a) providing a tissue biopsy sample; and

(b) determining the level of expression in said sample of the protein

consisting of the amino acid sequence **(SEQ ID NO: 2)**:

MAAAEGPVGDELWQTLVPLNHVFLRLREGLKNQSPTEAEKPASSSLPSSPPPQLLTRNVVFGGLGDEL  
FLWDGEDSSFLVVRRLRGPSGGGEEPALSQYQRLLCINPPLFEIYQVLLSPTQHHVALIGIKGLMVLELPK  
RWGKNSEFEGGKSTVNCSTTPVAERFFTSSTSLTLKHAAWYPSEILDPHVLLTSDNVIRIYSLREPQTP  
TNVILSEAEESLVLNKGAYTASLGETAVAFDFGPLDAVPKTLFGQNGKDEVVAYPLYILYENGETF  
LTYISLLHSPGNIWKAVGSIAHASAAEDNYGYDACAVLCLPCVPNILVIATESGMLYHCVVLEGEEDD  
HTSEKSWDSRIDLIPSLYVFECVELELALKLASGEDDPFDSDFSCPVKLHRDPKCPSRYHCTHEAGVHS  
VGLTWIHKLHKFLGSDEEDKDSLQELSTEQKCFVEHILCTRPLPCRQPAPIRGFWIVPDILGPTMICITST  
YECLIWPLLSTVHPASPPLCTREDVEVAESSLRVLAETPDSFEKHRSILQRSVANPAFLKASEKDIAPP  
PEECLQLLSRATQVFREQYILKQDLAKEEIQRRVKLLCDQKKKQLEDLSYCREERKSLREMAERLADK  
YEEAKEKQEDIMNRMKKLLHSFHSSELPVLSDSERDMKKELQLIPDQLRHLGNAIKQVTMCKDYQQQK  
MEKVLSPKPTIILSA YQRKCIQSILKEEGEHIREMVKQINDIRNHVNF,

wherein a sample comprising said protein at a level of expression that is greater than non-cancer cells indicates that said sample comprises a cancer cell.

14. (Previously Presented) The method according to claim 13, wherein said cancer cell is a cell in an epithelial or mesenchymal tumor.

15. (Previously Presented) The method according to claim 13, wherein said tissue biopsy sample is from a mammal.

16. (Previously Presented) The method according to claim 15, wherein said mammal is a human.
17. (Previously Presented) The method of claim 13, wherein the step of determining the level of expression of said protein consisting of said amino acid sequence comprises binding an antibody to said protein.
18. (Previously Presented) The method of claim 13, wherein the step of determining the level of expression of said protein consisting of said amino acid sequence comprises annealing of a nucleic acid binding molecule specifically to a nucleic acid transcript encoding said protein.
19. (Previously Presented) The method of claim 17, wherein said antibody is a monoclonal antibody directed against said protein.
20. (Previously Presented) The method of claim 19, wherein said monoclonal antibody is the monoclonal antibody bearing the biological deposit accession number DSM ACC 2457.
21. (Previously Presented) The method of claim 17, wherein said antibody is a chimeric protein.
22. (Previously Presented) The method of claim 21, wherein said chimeric protein comprises at least one CDR region of the monoclonal antibody bearing accession number DSM ACC 2457.
23. (Currently Amended) A diagnostic kit comprising a protein binding molecule, wherein the protein binding molecule binds to the protein consisting of the amino acid sequence (SEQ ID NO: 2):

MAAAEGPVGDELWQTLPNHVVFLRLREGLKNQSPTEAEKPASSSLPSSPPPQLLTRNVVFGGLGEL  
FLWDGEDSSFLVVRRLRGPSGGGEEPALSQYQRLLCINPPLFEIYQVLLSPTQHHVALIGIKGLMVLELPK  
RWGKNSEFEGGKSTVNCSTTPVAERFFTSSTSLTKHAAWYPSEILDPHVVLLTSDNVIRIYSLREPQTP  
TNVIILSEAEESLVLNKGRAYTASLGETAVAFDFGPLDAVPKTLFGQNGKDEVVAYPLYILYENGETFL  
TYISLLHSPGNIWKAVGSIAHASAAEDNYGYDACAVLCLPCVPNILVIATESGMLYHCVVLEGEEDDH

TSEKSWDSRIDLIPSLYVFECVELELALKLASGEDDPFDSDFSCPVKLHRDPKCPSRYHCTHEAGVHSVG  
LTWIKHLHKFLGSDEEDKDSLQELSTEQKCFVEHILCTRPLPCRQPAPIRGFWIVPDILGPTMICITSTYEC  
LIWPLLSTVHPASPPLLCTREDVEVAESSLRVLAETPDSFEKHRSILQRSVANPAFLKASEKDIAPPPEEC  
LQLLSRATQVFREQYILKQDLAKEEIQRRVKLLCDQKKKQLEDLSYCREERKSLREMAERLADKYEEA  
KEKQEDIMNRMKKLLHSFHSSELPVLSDSERDMKKELQLIPDQLRHLGNAIKQVTMKKDYQQQKMEKV  
LSLPKPTIILSAYQRKCIQSILKEEGEHIREMVKQINDIRNHVNF.

24. (Currently amended) A diagnostic kit comprising a nucleic acid, wherein the nucleic acid anneals specifically to a nucleic acid transcript that encodes the protein consisting of the amino acid sequence **(SEQ ID NO: 2)**:

MAAAEGPVGDELWQTWLPNHVVFLRLREGLKNQSPTEAEKPASSSLPSSPPPQLLTRNVVFGLGDEL  
FLWDGEDSSFLVVRIRGPGSGGGEPAALSQYQRLLCINPPLFEIYQVLLSPTQHHVALIGIKGLMVLELPK  
RWGKNSEFEGGKSTVNCSTTPVAERFFTSSTSLTKHAAWYPSEILDPHVLLTSDNVIRIYSLREPQTP  
TNVILSEAEESLVLNKGAYTASLGETAVAFDFGPLDAVPKTLFGQNGKDEVVAYPLYIYENGETFL  
TYISLLHSPGNIWKAVGSIAHASAAEDNYGYDACAVLCLPCVPNILVIATESGMLYHCVVLEGEEDDH  
TSEKSWDSRIDLIPSLYVFECVELELALKLASGEDDPFDSDFSCPVKLHRDPKCPSRYHCTHEAGVHSVG  
LTWIKHLHKFLGSDEEDKDSLQELSTEQKCFVEHILCTRPLPCRQPAPIRGFWIVPDILGPTMICITSTYEC  
LIWPLLSTVHPASPPLLCTREDVEVAESSLRVLAETPDSFEKHRSILQRSVANPAFLKASEKDIAPPPEEC  
LQLLSRATQVFREQYILKQDLAKEEIQRRVKLLCDQKKKQLEDLSYCREERKSLREMAERLADKYEEA  
KEKQEDIMNRMKKLLHSFHSSELPVLSDSERDMKKELQLIPDQLRHLGNAIKQVTMKKDYQQQKMEKV  
LSLPKPTIILSAYQRKCIQSILKEEGEHIREMVKQINDIRNHVNF.

25. (Previously Presented) The kit of claim 23 further comprising in whole or in part, the protein consisting of said amino acid sequence, for use as a control sample.

26. (Previously Presented) The kit of claim 24 further comprising in whole or in part, the protein consisting of said amino acid sequence, for use as a control sample.

27. (Canceled)

28. (Canceled)

29. (Previously Presented) The method of claim 17, wherein said antibody is a natural antibody, a recombinant antibody or a chimeric protein.